SYS · drug.AI · V0.1 (BETA) · PATENT-PENDING
FOCUS · RARE ONCOLOGY
PROGRAMS · ST-001 · ST-002
LAST UPDATE · 2026-01-08
PRESS · info@siloamtherapeutics.com
STATUS · NOMINAL
News & Publications

Milestones, papers,
and press.

The public trail of what we've shipped and what we've learned. Papers include negative results — we publish those too.

01 · Recent

Recent updates.

2026 · 01 · 08
Milestone
Peptide modality development kicks off — cyclic and macrocyclic capabilities expected to enter discovery in 2026
2025 · 11 · 12
Milestone
drug.AI Platform v0.1 (Beta) released — reasoning graph and human-in-the-loop review gates go live across all agents
2025 · 08 · 27
Press
Dr. Dony Ang and Linna Makmura co-found Siloam Therapeutics to build agentic AI for rare-oncology drug discovery
02 · Publications

Selected papers.

Peer-reviewed publications and dissertation from our founding team — indexed on Google Scholar.

Pharmaceuticals · 2024

De novo drug design using transformer-based machine translation and reinforcement learning of an adaptive Monte Carlo tree search

Ang D., Rakovski C., Atamian H.S. · Pharmaceuticals 17(2), 161
Doctoral Dissertation · 2024

Advancement in in-silico drug discovery: from virtual screening and molecular dockings to de-novo drug design with transformer-based generative AI and reinforcement learning

Ang D. · Chapman University
Biology · 2023

Virtual and in vitro screening of natural products identifies indole and benzene derivatives as inhibitors of SARS-CoV-2 main protease (Mpro)

Ang D., Kendall R., Atamian H.S. · Biology 12(4), 519
03 · Press

For press inquiries.

Journalists and analysts: reach us at info@siloamtherapeutics.com. We aim to respond within one business day.